



Abbott India Limited
Godrej BKC, Plot C-68,"G"Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071.India

Tel: (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN: L24239MH1944PLC007330

August 12, 2025

Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001

Scrip Code: 500488

Dear Sirs,

Sub: Outcome of Board Meeting

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Below is the outcome of the Board Meeting held today i.e., August 12, 2025:

Financial Results

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2025, along with the Limited Review Report issued by Walker Chandio & Co. LLP, Statutory Auditors of the Company. Copy of the same is enclosed herewith.

Appointment of Director

Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, upon recommendation of the Nomination and Remuneration Committee, the Board of Directors:

- a) Approved the appointment of Mr. Darshan Gada (DIN: 08174581) as an Additional (Non-Executive) Director of the Company with effect from August 18, 2025, subject to the approval of the Shareholders.
- b) Approved the Postal Ballot Notice to seek approval of the Shareholders for the above-mentioned appointment.

The Postal Ballot Notice shall be sent to the Shareholders in due course and the same shall be filed with the Stock Exchange.

Details pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, is enclosed as Annexure.

The Meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 1.00 pm.

This is for your information and record.

For **Abbott India Limited**

Sangeeta Shetty
Company Secretary
Membership No.: ACS 18865

Encl: a/a



Abbott India Limited
Godrej BKC, Plot C-68, "G" Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051, India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071, India

Tel : (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN : L24239MH1944PLC007330

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(Rs. in Crores except earnings per share)

	Particulars	Quarter ended			Year ended
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		Unaudited	Refer Note 4	Unaudited	Audited
1	Income				
	(a) Revenue from operations	1,738.35	1,604.59	1,557.61	6,409.15
	(b) Other income	72.84	76.02	67.33	275.58
	Total Income	1,811.19	1,680.61	1,624.94	6,684.73
2	Expenses				
	(a) Cost of materials consumed	146.18	186.68	146.28	621.12
	(b) Purchases of stock-in-trade	868.79	787.36	781.30	3,056.34
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(72.85)	(118.08)	(81.22)	(180.68)
	(d) Employee benefits expense	168.01	144.40	161.06	587.54
	(e) Finance costs	5.82	3.92	2.75	11.43
	(f) Depreciation and amortisation expense	19.48	17.93	18.37	71.80
	(g) Other expenses	182.63	175.69	159.18	630.23
	Total Expenses	1,318.06	1,197.90	1,187.72	4,797.78
3	Profit before tax (1-2)	493.13	482.71	437.22	1,886.95
4	Tax expenses				
	(a) Current tax expense	127.77	122.75	112.72	477.99
	(b) Tax adjustment for earlier years	-	(8.16)	(1.35)	(8.20)
	(c) Deferred tax expense/(credit)	(0.50)	1.08	(2.16)	2.72
	Total Tax Expenses	127.27	115.67	109.21	472.51
5	Profit for the period / year (3-4)	365.86	367.04	328.01	1,414.44
6	Other Comprehensive Income / (Loss)				
	Items that will not be reclassified subsequently to Profit or Loss	0.05	(7.27)	0.01	(7.25)
	Income tax on above	(0.01)	1.83	-*	1.83
	Total Other Comprehensive Income / (Loss) , net of tax	0.04	(5.44)	0.01	(5.42)
7	Total Comprehensive Income for the period / year, net of tax (5+6)	365.90	361.60	328.02	1,409.02
8	Paid-up Equity Share Capital				
	(Face Value of Rs.10 per Equity Share)	21.25	21.25	21.25	21.25
9	Other Equity	-	-	-	4,211.90
10	Earnings per equity share - Basic/Diluted				
	(of Rs.10/- each) (not annualised except for the year ended 31st March)	172.17	172.72	154.36	665.62

* Less than Rs. 50,000/-



NOTES :

- 1 The above financial results have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on August 12, 2025.
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The financial results for quarter ended June 30, 2025 have been subjected to limited review by the statutory auditors of the Company. The Limited Review Report does not contain any qualifications.
- 4 The figures for the quarter ended March 31, 2025 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year which were only reviewed and not subjected to audit.
- 5 The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- 6 Figures for the previous periods have been regrouped/reclassified wherever considered necessary.

Place : Mumbai
Date : August 12, 2025



For and on behalf of the Board of Directors of
Abbott India Limited

Kartik Rajendran
Managing Director
DIN : 09527717

Walker ChandioK & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Abbott India Limited


1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Abbott India Limited** ('the Company') for the quarter ended **30 June 2025**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Abbott India Limited
Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company
pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (as amended)

5. The review of unaudited quarterly financial results for the period ended 30 June 2024 included in the Statement was carried out and reported by S R B C & CO LLP, Chartered Accountants, who have expressed unmodified conclusion vide their review report dated 07 August 2024 whose report has been furnished to us and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandio & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013



Ashish Gupta
Partner
Membership No. 504662

UDIN:- 25504662BMOOHA2372

Place: Mumbai
Date: 12 August 2025

Annexure

Sr. No.	Particulars	Details of Appointment
1.	Reason for change	Appointment of Mr. Darshan Gada as Additional (Non-Executive) Director of the Company.
2.	Date of Appointment and Term	Appointed as an Additional (Non-Executive) Director of the Company with effect from August 18, 2025, subject to the approval of Shareholders.
3.	Brief Profile	 Darshan Gada brings over 21 years of extensive and diverse experience in Finance, spanning Commercial Operations, Taxation, Supply Chain Finance, Merger & Acquisitions and Strategy. Known for his forward-thinking approach, Darshan has led numerous automation, gross margin improvement and cash flow management initiatives and is deeply committed to nurturing high-performing finance talent. He is currently serving as the Regional Finance Director at Abbott Healthcare Private Limited heading the Financial Planning and Analysis function for Abbott's Established Pharmaceuticals business in India. Over his tenure at Abbott, he has held several key leadership roles such as - steering finance for a large commercial unit with accelerated growth, leading supply chain finance to drive cost leadership strategies, and shaping long-term business strategy developing and implementing Go to Market strategy for diversified business. His contributions also include business integration, Merger & Acquisitions, and core accounting. Darshan began his career at Deloitte, followed by a pivotal role at Piramal Healthcare in scaling the rural healthcare business. Darshan is a Chartered Accountant from the Institute of Chartered Accountants of India and holds a Commerce graduate degree from R. A. Podar College, Mumbai.
4.	Declaration pursuant to BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018	We hereby affirm that Mr. Darshan Gada is not debarred from holding the office of director by virtue of any order of the Securities and Exchange Board of India (SEBI) or any other such authority.
5.	Relationship Inter-se Directors/ Key Managerial Personnel	Mr. Darshan Gada is not related to any of the Directors or Key Managerial Personnel of the Company.